publicações selecionadas
-
artigo académico
- Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. Nature Reviews Urology. 2020
- 10.1038/s41585-019-0263-6. Nature Reviews Urology. 2020
- Is DNA content alteration a consequence of proliferative and differentiation changes in urothelial bladder tumours?. Ata Urológica Portuguesa. 2003
-
artigo de conferência
-
artigo de revista
- Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy. Cancers. 2023
- Understanding the bricks to build better surgical oncology unit at Maputo Central Hospital: prevalent surgical cancers and residents knowledge. Pan African Medical Journal. 2019
- Metabolic coupling in urothelial bladder cancer compartments and its correlation to tumor aggressiveness. Cell Cycle. 2016
- CD147 and MCT1 - potential partners in bladder cancer aggressiveness and cisplatin resistance. Molecular Carcinogenesis. 2015
- Stage at presentation of breast cancer in Luanda, Angola-a retrospective study. BMC Health Services Research. 2015
- Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients. Oncology Letters. 2014
- Low RKIP expression associates with poor prognosis in bladder cancer patients. Virchows Archiv. 2013
- Predictive biomarkers of bacillus Calmette-Guérin immunotherapy response in bladder cancer: Where are we now?. Advances in Urology. 2012
- The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion - The prognostic contribution of related molecular markers. Histopathology. 2009
-
capítulo de livro
-
documento
- Efeito sensibilizador da darifenacina a agentes citotóxicos no cancro pancreático: estudo in silico e em linhas celulares 2022
- Hexokinase II (HKII) as prognostic biomarker and target for bladder cancer therapy 2022
- Targeting Chitinase-like-1 (CHI3L1) as a therapeutic target for pancreatic cancer 2021
- Targeting chitinase 3-like 1 in pancreatic cancer: in silico identification of inhibitors from a DrugBank database and confirmation of growth inhibition effect in cell lines 2021
- Hexokinase II (HKII) is a prognostic biomarker for bladder cancer patients: Antitumoral activity of the HKII inhibitor 2-deoxy-D-glucose 2021
- Upregulation of Hexokinase II (HKII) impacts survival of bladder cancer patients: Effects of HKII inhibition by 2-deoxy-D-glucose 2021
- Metabolic remodelling in cisplatin-resistant bladder cancer 2020
- Cisplatin-resistant urothelial bladder cancer cells undergo metabolic reprogramming 2019
- Cisplatin-resistant urothelial bladder cancer cells undergo metabolic reprogramming. 2019
- The metabolic coupling among urothelial bladder cancer compartments predicts tumour aggressiveness and chemoresistance 2015
- CD147 and MCT1: Potential partners in bladder cancer aggressiveness and cisplatin resistance 2013
- RKIP downregulation associates with poor prognosis in bladder cancer patients 2013
- RKIP downregulation associates with poor prognosis in bladder cancer patients 2012
- CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis 2011
- Estudo da Imunoexpressão dos Grupos Sanguíneos ABO em Carcinomas Uroteliais Superficiais e Invasores 2002